Our foundational study demonstrating that helminth-derived secretome proteins confer significant protection against colitis in preclinical models — validated against human ulcerative colitis patient tissue ex vivo. This is the primary evidence base for the MBT platform and the scientific rationale for MBT-001 and MBT-002.
Describes the discovery and pre-clinical testing of Na-AIP-1, a novel recombinant protein derived from Necator americanus. The protein suppressed acute and chronic colitis models in mice and inhibited inflammatory cytokine secretion by human T cells — establishing the proof of concept that individual secretome proteins can replicate the immune-modulating effect of the whole parasite.
Demonstrates that a recombinant hookworm-derived protein drives regulatory T cell responses capable of suppressing airway inflammation in asthma models — establishing the scientific basis for MBT's platform expansion beyond IBD and into allergic and inflammatory lung disease.
The pioneering clinical study by Macrobiome collaborator Dr John Croese establishing that treatment of Crohn's Disease patients with Necator americanus was well-tolerated and resulted in reduced Crohn's Disease Activity Index (CDAI) scores — the clinical proof of concept that underpins the entire MBT therapeutic strategy.